Kylie N. Barnes

Kylie N. Barnes

Auto-generated profile, based on publicly available information

Kylie N. Barnes

Division of Pharmacy Practice and Administration, University of Missouri-Kansas City School of Pharmacy, Kansas City, MO, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
KBKylie N. Barnes
Kylie N. Barnes
CVClaire M. Vogl
Claire M. Vogl
LNLeigh Anne Nelson
Leigh Anne Nelson
Objective: The objective of this study was to review the characteristics, efficacy, and safety of zuranolone in the management of postpartum depression (PPD). Data sources: Literature was identified using PubMed (1966-August 2023) and EMBASE (1973-August 2023) and clinicaltrials.gov. Search terms included zuranolone, SAGE-217, and PPD with further limitation of those published in English. Study selection and data extraction: Articles selected for inclusion included trials evaluating zuranolone for the treatment of PPD. Data synthesis: Zuranolone was evaluated for the treatment of moderate to severe PPD in 2 phase III trials. Both studies resulted in statistically significant improvement in depressive symptoms at day 15 ( P = 0.003 and P < 0.001). Sustained differences in remission rates favoring zuranolone were found in both studies at day 45 compared with placebo ( P = 0.01 and P < 0.05). Zuranolone was well tolerated, with somnolence, dizziness, headache, and sedation reported as the most common side effects. Relevance to patient care and clinical practice in comparison to existing drugs: Zuranolone is only the second medication approved by the Food and Drug Administration (FDA) for PPD and offers an advantage over brexanolone in that it can administered orally in the outpatient setting. The rapid onset of effect of zuranolone is advantageous to traditional antidepressant therapy which can be weeks to months; however, limited information is available on safety during lactation. Conclusions: The recent FDA approval of oral zuranolone for PPD offers a second rapid-acting treatment for PPD, extending the opportunity for treatment to patients in the outpatient setting.

16 March 2024 in American Journal of Pharmaceutical Education
Verified
Journal Article
Closed access
KBKylie N. Barnes
Kylie N. Barnes
KHKaren L. Hardinger
Karen L. Hardinger
MGMaqual R. Graham
Maqual R. Graham

2 May 2022 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
KBKylie N. Barnes
Kylie N. Barnes
AYAbigail M. Yancey
Abigail M. Yancey
AFAlicia B. Forinash
Alicia B. Forinash
Objective: To review the pharmacology, efficacy, and safety of ibrexafungerp in the management of vulvovaginal candidiasis (VVC). Data Sources: Literature was sought using PubMed (1966—February 2022) and EMBASE (1973—February 2022), and clinicaltrials.gov. Search terms included ibrexafungerp, SCY-078, and VVC. Study Selection and Data Extraction: All studies including humans and published in English with data assessing the efficacy and safety of ibrexafungerp for the treatment of VVC were evaluated. Data Synthesis: A phase 2 dose-finding study found ibrexafungerp had similar efficacy to fluconazole in the clinical cure of VVC (51.9% vs 58.3%, respectively). Two phase 3 clinical trials demonstrated ibrexafungerp had statistical superiority over placebo for clinical cure in moderate to severe VVC ( P < 0.001 and P = 0.023, respectively). The most frequently reported adverse reactions in the clinical trials were gastrointestinal-related symptoms. To date, data comparing efficacy of ibrexafungerp and topical imidazoles in the treatment of VVC are nonexistent. Relevance to Patient Care and Clinical Practice: Topical imidazoles and oral fluconazole are effective for the treatment of uncomplicated VVC. Due to increased resistance, limited fluconazole coverage for non- Candida albicans species, and potential for significant drug interactions associated with fluconazole use, alternative treatments for VVC are needed. Ibrexafungerp is a new oral triterpenoid antifungal agent indicated for the treatment of VVC. Additional clinical trials are needed to evaluate long-term safety data as well as efficacy and safety in specialty populations. Conclusion: Ibrexafungerp, a recently approved triterpenoid antifungal agent, is an effective and well-tolerated option for the treatment of VVC.

1 April 2022 in American Journal of Pharmaceutical Education
Verified
Journal Article
Open access
PDF file
RSRebecca H. Stone
Rebecca H. Stone
NCNicole Cieri-Hutcherson
Nicole Cieri-Hutcherson
VVVeronica Vernon
Veronica Vernon
RARegina Arellano
Regina Arellano
CMCortney Mospan
Cortney Mospan
KVKathleen Vest
Kathleen Vest
Starting in 2014, the pharmacist’s role in the United States (US) has expanded to include prescribing hormonal contraception (HC), and is currently addressed with policy in 14 states and Washington D.C.. Training and education requirements for this expanded scope of practice vary between states and are changing rapidly. The objective of this review is to examine how student pharmacists are taught to provide contraceptive care, specifically for prescribing ongoing HC and emergency contraception, and to identify potential gaps in current US pharmacy curricula. Despite steady adoption into community pharmacy practice, currently there is sparse literature assessing educational methods used to teach contraceptive care. This review offers recommendations to promote consistent and comprehensive student pharmacist education in providing contraceptive care across institutions, regardless of state policy status.

25 November 2022 in Journal of Pharmacy Practice
Verified
Journal Article
Closed access
KBKylie N. Barnes
Kylie N. Barnes
LLLauren D. Leader
Lauren D. Leader
NCNicole Cieri-Hutcherson
Nicole Cieri-Hutcherson
JKJulie Kelsey
Julie Kelsey
MHMary F. Hebert
Mary F. Hebert
SMSarah McBane
Sarah McBane
Complications throughout the peripartum period may be caused by preexisting conditions or pregnancy-induced conditions and may alter pharmacotherapy management. Pharmacotherapy management during late pregnancy and delivery requires careful consideration due to changing hormones, hemodynamic status, and pharmacokinetics, and concerns for potential maternal and/or fetal morbidity. Increased maternal and fetal monitoring are often required and may lead to therapy changes. Pharmacists, as key members of the interprofessional team, can contribute essential perspective to the management of postpartum pharmacotherapy through assessment and recommendation of appropriate and judicious use of medications.

10 March 2014 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
KBKylie N. Barnes
Kylie N. Barnes
EPErica F. Pearce
Erica F. Pearce
AYAbigail M. Yancey
Abigail M. Yancey
AFAlicia B. Forinash
Alicia B. Forinash
Objective: To review the pharmacology, efficacy, and safety of ospemifene in the management of dyspareunia. Data Sources: Literature was sought using PubMed (1966-January 2014) and EMBASE (1973-January 2014). Search terms included ospemifene, FC-1271a, dyspareunia, vulvovaginal atrophy, and vaginal atrophy. Study Selection and Data Extraction: All studies, including studies on humans, published in English with data assessing the efficacy and safety of ospemifene in the management of dyspareunia were evaluated. Data Synthesis: Ospemifene is a new oral estrogen receptor agonist/antagonist indicated for moderate to severe dyspareunia. Clinical trials evaluating efficacy have shown a significant improvement in superficial cells, parabasal cells, vaginal pH, vaginal dryness, and dyspareunia. The most frequently reported adverse drug reactions in the clinical trials included hot flashes, vaginal discharge, muscle spasms, and hyperhidrosis. Similar to systemic estrogen, boxed warnings with ospemifene include risk for thromboembolism and cerebrovascular disease. Additionally, patients with a uterus still need to use a progestogen with ospemifene to reduce the risk of hyperplasia. Conclusions: Ospemifene has been effective in improving symptoms of vulvovaginal atrophy when compared with placebo; however, no studies comparing ospemifene with estrogen products exist. Additional clinical trials are needed to evaluate the efficacy and safety in specialty populations, and long-term safety data are needed to assess the potential for serious adverse events. With the risks being similar to that for systemic estrogen therapy, ospemifene appears to be an alternative agent to estrogen therapy but does not have any advantages over estrogen.